| Kristen Brogna, LMHC | |
|
872 Massachusetts Ave. Ste 2-2, Ste 2-2, 2-7, Cambridge, MA 02139 | |
| (617) 395-5806 | |
| Not Available |
| Full Name | Kristen Brogna |
|---|---|
| Gender | Female |
| Speciality | Counselor - Professional |
| Location | 872 Massachusetts Ave. Ste 2-2, Cambridge, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063534220 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | 5476 (Massachusetts) | Secondary |
| 101YP2500X | Counselor - Professional | 5476 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kristen Brogna, LMHC 1000 Jefferson St., Ste. 2-2, 2-7, Lynchburg, VA 24504 Ph: (617) 379-0496 | Kristen Brogna, LMHC 872 Massachusetts Ave. Ste 2-2, Ste 2-2, 2-7, Cambridge, MA 02139 Ph: (617) 395-5806 |
News Archive
Professional baseball players struggle to return to a high level of play after biceps tenodesis (BP) surgery, according to research presented today at the American Orthopaedic Society for Sports Medicine's Specialty Day in San Diego. The study examined how players with SLAP tears responded to biceps tenodesis.
Training community health workers to perform verbal autopsy interviews captured more accurate and complete data about the number and causes of deaths in a rural sub-county of Uganda than current health facility-dependent surveillance methods, according to researchers at the University of North Carolina at Chapel Hill and their in-country partners.
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that it has filed an application with China's Food and Drug Administration to conduct a Phase 2 clinical trial in fibrolamellar carcinoma (FLC) patients in China for its proprietary drug candidate, ENMD-2076.
Non-alcoholic fatty liver disease, which may soon be the leading indication for liver transplant, is found to be significantly associated with worse transplant outcomes. In addition, a new tool for diagnosing NAFLD represents an alternative to liver biopsy, which is more expensive and prone to complications, and ultrasound and alfafeprotein blood test screening are an effective alternative to CT scan and MRI for patients with cirrhosis at high risk for hepatocellular cancer.
› Verified 6 days ago
Glorimar Gonzalez-raices, Counselor Medicare: Not Enrolled in Medicare Practice Location: 20 Dudley St, Cambridge, MA 02140 Phone: 413-265-4794 | |
Ms. Gopi Dhokai, LMHC Counselor Medicare: Not Enrolled in Medicare Practice Location: 545 Concord Ave Ste 14, Cambridge, MA 02138 Phone: 240-506-9768 | |
Marisa Anderson, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1158 Massachusetts Ave Fl 3, Cambridge, MA 02138 Phone: 857-314-0554 | |
Mr. Pavan S. Brar, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1493 Cambridge St Rm 239, Cambridge, MA 02139 Phone: 617-575-5399 | |
Carlos Suarez, M.A. Counselor Medicare: Not Enrolled in Medicare Practice Location: 5 Sacramento St, Cambridge, MA 02138 Phone: 617-354-2275 Fax: 617-547-4356 | |
Susan M Dingsor, Counselor Medicare: Not Enrolled in Medicare Practice Location: 350 Cambridge St, Cambridge, MA 02141 Phone: 617-547-0909 | |
Suad N Warsame, Counselor Medicare: Not Enrolled in Medicare Practice Location: 52 Trowbridge St Apt 11, Cambridge, MA 02138 Phone: 617-270-1725 |